B
179.35
-0.92 (-0.51%)
| Penutupan Terdahulu | 180.27 |
| Buka | 177.15 |
| Jumlah Dagangan | 276,034 |
| Purata Dagangan (3B) | 370,548 |
| Modal Pasaran | 20,238,571,520 |
| Harga / Pendapatan (P/E Ke hadapan) | 384.62 |
| Harga / Jualan (P/S) | 6.06 |
| Harga / Buku (P/B) | 5.96 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Feb 2025 - 28 Feb 2025 |
| Margin Keuntungan | -25.50% |
| Margin Operasi (TTM) | -13.90% |
| EPS Cair (TTM) | -8.18 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 39.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 30.54% |
| Nisbah Semasa (MRQ) | 1.94 |
| Aliran Tunai Operasi (OCF TTM) | -4.56 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.26 B |
| Pulangan Atas Aset (ROA TTM) | -9.58% |
| Pulangan Atas Ekuiti (ROE TTM) | -23.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | BeiGene, Ltd. | Menaik | Menurun |
AISkor Stockmoo
-0.2
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.20 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene’s revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Growth |
| % Dimiliki oleh Orang Dalam | 17.79% |
| % Dimiliki oleh Institusi | 44.98% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 300.00 (Morgan Stanley, 67.27%) | Beli |
| Median | 260.00 (44.97%) | |
| Rendah | 235.00 (JP Morgan, 31.03%) | Beli |
| Purata | 265.00 (47.76%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 207.36 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 03 Dec 2024 | 300.00 (67.27%) | Beli | 206.01 |
| TD Cowen | 13 Nov 2024 | 260.00 (44.97%) | Beli | 195.45 |
| JP Morgan | 22 Oct 2024 | 235.00 (31.03%) | Beli | 220.63 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | - | 207.62 | -1,037,017 | -215,305,470 |
| OYLER JOHN | - | - | 0 | 0 |
| WANG XIAODONG | - | 187.50 | -41,760 | -7,830,000 |
| Jumlah Keseluruhan Kuantiti Bersih | -1,078,777 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -223,135,470 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 197.56 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| OYLER JOHN | Pegawai | 14 Dec 2024 | Pelaksanaan pilihan | 1,300,000 | - | - |
| WANG XIAODONG | Pengarah | 10 Dec 2024 | Jual automatik (-) | 41,760 | 187.50 | 7,830,000 |
| WANG XIAODONG | Pengarah | 10 Dec 2024 | Pelaksanaan pilihan | 41,760 | - | - |
| BAKER BROS. ADVISORS LP | Pengarah | 09 Dec 2024 | Jual (-) | 1,037,017 | 207.62 | 215,305,470 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |